02.12.26 -- Why Your MVP And Its Evolution Matters To Manufacturing

ISO 21973 establishes the global best practices for transporting cell and gene therapies, ensuring quality, safety, and consistency across complex supply chains critical to patient outcomes.

Economic pressures, funding shifts, and evolving therapeutic pipelines are reshaping CDMO capacity in 2025, with 2026 expected to bring intensified competition and strategic realignments.

Downstream AAV manufacturing remains a critical bottleneck, and overcoming it requires platforming that couples standardized processes with a scalable CMC system to improve speed, cost, and program viability.

Explore facility cleaning, monitoring, and disinfection strategies to meet regulatory standards, emphasizing planning, stakeholder involvement, testing, trending, documentation, and continuous improvement.

Non-viral gene editing is a powerful method for cell therapy. Learn how to address key challenges like cell viability and thermal damage with an innovative approach designed to improve performance.

Proactively understanding containment system performance can streamline development and accelerate market delivery. Review comparative data for CZ-based systems and traditional glass or polypropylene options.

Learn how this game-changing platform simplifies the complex process of custom media design, empowering researchers to expedite their development and achieve optimal results.

Discover how scalable, cost-effective, and high-quality lentiviral vector manufacturing can support both ex vivo and emerging in vivo CAR-T therapies.

Reducing biological manufacturing costs requires strategic late-stage process development, yield optimization, scale-up, and raw material substitution—all while maintaining product quality and regulatory compliance.

Eliminating discontinuity between R&D and cGMP manufacturing, through mirrored environments, accelerates the journey to IND and patient access and bypasses delays in clinical transfer.